PRM-151 is an experimental medication being developed and tested by Promedior, Inc. PRM-151 is a protein called human pentraxin-2 that is grown and purified ...

The majority of pipeline drugs in development are administered via the oral route. High-impact upcoming events in the IPF space comprise topline Phase IIa trial ...

Nov 11, 2020 ... ... Professor of Chemistry and Presidential Scholar for Drug Discovery, has led a team to develop two targeted therapies for people with IPF.

Nintedanib and pirfenidone were approved by the FDA for the treatment of IPF in 2014 based on positive phase 3 trials, and both of these antifibrotic drugs are ...

May 17, 2018 ... ... pirfenidone and nintedanib, for the treatment of idiopathic pulmonary fibrosis ( IPF) has fueled interest in the development of additional drugs ...

Sep 17, 2019 ... The other drug approved by the FDA for IPF is Genentech's Esbriet. That drug, first developed by Brisbane, Calif.-based InterMune, was ...

Nov 4, 2019 ... Industry-sponsored drugs in active clinical development for IPF are spread evenly across Phase I and Phase II, with two drugs in Phase III.

Boehringer Ingelheim has developed OFEV ® (nintedanib), an antifibrotic drug shown to slow disease progression by reducing lung function decline and ...

Overcome Translational & Clinical Challenges to Develop More Effective & Disease-Modifying IPF Drugs. Accelerate the Development of More Meaningful &  ...

Drug development in IPF has proven challenging with exceedingly high clinical trial failure rates. With the goal of delivering safe and effective therapies to our ...